



Advancing Cardiac Ablation

FOR IMMEDIATE RELEASE

Contact: Martin Sklar, CEO, 781-248-6841, msklar@ablaacor.com

USPTO allows AblaCor™ five ablation *catheter-anchoring* patents for its CircumBlator™ AF Catheter Ablation System

CircumBlator is designed to reduce or eliminate the 30% failure rate of existing pulmonary vein isolation (PVI) procedures for treatment of stroke-causing and life-debilitating Atrial Fibrillation (AFib), an industry currently generating \$1.2 billion in medical device sales treating 300,000 patients annually.

CircumBlator's innovative *anchoring* technology is designed to ensure that the ablation device is secured against the atrial wall during the entire ablation procedure, thus overcoming a key issue associated with the 30% failure rate of currently marketed products.

NEEDHAM, Mass., March 5, 2018—[AblaCor Medical Corporation](#) announced today that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) on five additional patents for its **CircumBlator™ AFib Catheter Ablation System** to advance pulmonary vein isolation (PVI) ablation procedures for patients with atrial fibrillation (AFib)—the most common irregular heart rhythm and a potentially deadly disorder. When issued, AblaCor will have a total of nine patents issued for its CircumBlator system, with several more pending. Although AblaCor's technology is designed to address AFib, the patent portfolio also has been developed to include additional medical procedures.


"AFib is a major international epidemic," said **Martin Sklar**, CEO of AblaCor. "CircumBlator is designed to overcome the drawbacks of other ablation technologies due to their unpredictability in producing durable, continuous, transmural lesions. In fact, recurrence of AFib after treatment with currently available technologies is reported in the scientific literature to be approximately 30 percent." ([Source: "Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients with Paroxysmal Atrial Fibrillation." *Circulation*. 2015;132:1311-1319.](#))

AblaCor also announced that it has established a Scientific Advisory Board (SAB) with the appointment of prominent electrophysiologist **Lawrence Rosenthal, MD, PhD, FACC, FHRS**, who is Director of Electrophysiology Service and Professor of Medicine, UMass Memorial Medical Center. "AblaCor's novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance," said Dr. Rosenthal.

(more)

CircumBlator is designed to enable durable pulmonary vein isolation (PVI) and differs fundamentally from *point-by-point* and *balloon* approaches to cardiac ablation treatment of AFib patients (see below):

| | CircumBlator™ | Point-by-Point | Balloon |
|---|---------------|----------------|---------|
| Anchor stabilizes electrode-tissue contact | ✓ | X | X |
| Precise, controlled energy delivery | ✓ | X | X |
| Consistent lesions encircling PVs | ✓ | X | X |



CircumBlator™ AF Catheter Ablation System

Catheter ablation devices are used in a procedure known as **Pulmonary Vein Isolation (PVI)**, which is the cornerstone treatment performed for most AFib patients having an ablation. The purpose of PVI is to create a quality lesion of destroyed tissue encircling the pulmonary veins (PVs) at their entrance into the right atrium (top chamber of the heart). Quality, complete lesions prevent electrical signals originating in the PVs from entering the atria. A quality lesion for PVI is defined by creation of a full-wall depth (~ 4mm in normal hearts) and continuous lesion ring around each

(more)

PV and/or encirclement of all the PVs. It is the current consensus of electrophysiologists and cardiologists that a quality lesion performed during PVI can be curative for early-stage or paroxysmal AFib patients.

About Ablacor™ Medical Corporation

Ablacor is an early-stage medical device company headquartered near Boston. Its initial product is the CircumBlator™ AF Catheter Ablation System to advance the standard *pulmonary vein isolation* (PVI) procedure for patients with atrial fibrillation (AFib), the most common irregular heart rhythm and a potentially deadly disorder. CircumBlator is designed to overcome the limitations of currently available ablation catheters for treating AFib by producing durable, continuous, transmural lesions. Ablacor has a strong portfolio of patents issued and pending.

-END-